Morningstar

AbbVie Gets Europe OK for Rinvoq in Vitiligo, Alopecia Areata

Provided by Dow Jones

By Colin Kellaher 




  AbbVie has won European regulatory approval for the expanded use of its blockbuster drug Rinvoq in the autoimmune diseases vitiligo and alopecia areata. 



  AbbVie on Wednesday said the European Commission approvals cover Rinvoq for the treatment of people ages 12 an older with severe alopecia areata, which causes a range of hair loss patterns, and with the depigmenting disorder non-segmental vitiligo. 



  The North Chicago, Ill., biopharmaceutical company said the green light makes Rinvoq the first systemic medication available in Europe for patients with non-segmental vitiligo, the most common form of vitiligo, which is marked by symmetrical and bilateral depigmented white patches of skin. 



  AbbVie has previously said it expects revenue from Rinvoq, which is already approved for use in several autoimmune diseases, to top $10 billion this year. 





  Write to Colin Kellaher at colin.kellaher@wsj.com 





  (END) Dow Jones Newswires



  July 29, 2026 06:10 ET (10:10 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
4 Stocks to Buy Before They Rise Further
 
Plus, the member of the triple-digit club reporting earnings this week. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
2 Undervalued Stocks to Buy Before They Rebound
 
These wide-moat stocks look attractive after their recent pullbacks. 
 
 
Susan Dziubinski 
 
 
 
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
 
Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options. 
 
 
Russel Kinnel and Ivanna Hampton 
 
 
 
The 10 Best Dividend Stocks
 
These are the top dividend-paying stocks to buy today. 
 
 
Susan Dziubinski 
 
 
 
 

			Sponsor Center